Maastricht Univerisity Medical Center Commences Procedures
24.2.2021 23:47:00 EET | Business Wire | Press release
Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Maastricht University Medical Centre+ (MUMC+) in the Netherlands has commenced procedures since the extended lockdowns across Europe precluded elective surgeries. The team at MUMC+ successfully performed two atrial flutter ablations yesterday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006030/en/
Dr. Marisevi Chaldoupi performing an atrial flutter ablation with Imricor's products at MUMC+ in a standard MRI suite equipped to function as an iCMR lab (Photo: Business Wire)
Electrophysiologist, Dr. Marisevi Chaldoupi, MD PhD, commented: “Today in our ablation we realized that we were limited in the past, and now we can see what we are doing. While we have just started in iCMR, it is obvious to see the future of this technology and where it will take us and patient treatment.”
Imricor’s Chair and CEO, Steve Wedan, commented: “This is great news and an exciting step forward, as we start to put COVID behind us. We continue to actively plan for the easing of COVID restrictions, including scheduling training and installation at new sites and supporting the recommencement of procedures at existing sites. We also expect to begin signing new labs again soon, growing our installed base.
“Notably, MUMC+ is one of the sites where cardiology and radiology are partnering to utilize an existing MRI suite as an iCMR lab as a way to start performing ablations using Imricor’s products immediately, while future plans are being made for constructing dedicated iCMR lab facilities. They are a model for other sites who want to get started in a similar way.”
Dr Miranda Bijvoet, MD (imaging Cardiologist) and Dr Casper Mihl, MD (Radiologist) together stated: “Today proved that it is feasible to turn a diagnostic MR into an iCMR lab, and the technique has great potential as we were able to evaluate the ablation lesion and validate the treatment in the right position. This is a great collaboration between cardiology and radiology.”
Rob Holtackers, PhD (MR Physicist) added: “Combining the best imaging with the best of electrophysiology practice allows us to provide better patient care. The partnership is making this amazing project work.”
About Imricor
Please visit http://imricor.com/investors/about-imricor/ for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224006030/en/
Contact information
Investors:
Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com
Investors & Australian Media:
Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028
Rest of World Media:
Nick Twohy
Director of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Modon's Hudayriyat Golf Estates Sets UAE Record With More Than AED 13 Billion in Sales Within Days of Launch7.7.2026 21:36:00 EEST | Press release
Modon has set a new benchmark for the UAE real estate market with the launch of Hudayriyat Golf Estates on Hudayriyat Island, Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707126559/en/ Modon's Hudayriyat Golf Estates sets UAE record with more than AED 13 billion in sales within days of launch (Photo: AETOSWire) Within days of launch, the community achieved record-breaking sales exceeding AED 13 billion, marking the highest publicly recorded sales value for a single residential project launch in the UAE. Comprising an exclusive collection of golf mansions, villas, and townhouses, the development saw 1,700 of its residences sold after few days of launch. The response from buyers and investors reflects confidence in Abu Dhabi’s real estate market and Modon’s development vision, while reinforcing Hudayriyat Island’s position as a premier lifestyle destination. Designed around privacy, wellbeing and premium living
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 17:36:00 EEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 16:35:00 EEST | Press release
Integral Ad Science (IAS), one of the world's most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS's long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized, advertisers increasingly need trusted intelligence to make real-time decisions. Jones's deep expertise across product, technology, and AI uniquely positions IAS to bu
Andersen Global Adds Collaborating Firm Abcoo Law Firm7.7.2026 16:30:00 EEST | Press release
Andersen Global strengthens its presence in Türkiye with collaborating firm Abcoo Law Firm, enhancing the organization’s existing platform in the country with the addition of legal capabilities. Founded in 2014, Abcoo advises local and international clients across a broad range of legal services, with experience in corporate and M&A, real estate and construction, dispute resolution, employment, compliance, banking and finance, competition and intellectual property law. The firm is consistently recognized as a top tier and leading firm by international publications, including The Legal 500. Abcoo supports organizations across a wide range of industries, including real estate and construction, retail, textile, cosmetics, automotive, logistics, chemicals, IT, energy, healthcare, manufacturing and financial services, providing strategic legal guidance and commercially focused solutions. “Our focus has always been on understanding each client’s objectives and providing practical, commercial
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 16:00:00 EEST | Press release
Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom